Pliant Therapeutics Inc. (PLRX) Stock: Dividends & Earnings

Company Overview:

Market Cap: $65.63M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $1.02 - $1.95

6.3 Year PLRX Performance Metrics:

Total Return (with DRIP): -95.1% (-37.98% CAGR)

Total Return (no DRIP): -95.1% (-37.98% CAGR)

Share Price: -95.1% (-37.98% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $493

Total Return $ (with DRIP): -$9,507

PLRX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

PLRX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for PLRX

Based on past 6.3-year performance, here are PLRX growth metrics:

Share price CAGR of -37.98%
Dividend CAGR of +0%

Using PLRX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	PLRX (DRIP)	PLRX - No DRIP
Current Price	$1.05	$1.05
Start Shares	9,523.81	9,523.81
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	9,523.81	9,523.81
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.01	$1.05
Total Dividends	$0	$0
Final Value	$84	$10,000

Estimated Future Value + Dividends - PLRX

NOTE: Above numbers are our estimate based on PLRX's Dividend and Price CAGR over past 6.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Pliant Therapeutics Inc. (PLRX) had its IPO on , and is traded on NASDAQ stock exchange.

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.

PLRX website: https://pliantrx.com